Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CMAB Biopharma of Suzhou Announces $34 Million Series B

publication date: Apr 2, 2018

CMAB Biopharma of Suzhou announced a Series B of $34 million led by CDBI Partners, with C-Bridge Capital, Cormorant, Qianhai FoF Fund and Tigermed participating. The funds will be used to equip a GMP manufacturing facility compliant with China, US, EU and ICH standards. Three months ago, CMAB raised $38 million in a Series A funding led by C-Bridge Capital and BioBAY Park.The facility will contain production, purification and injection filling lines with reactors varying from 50L to 2000L, aiming to provide CDMO services for global clients in Phase I/II trials. More details.... 


Share this with colleagues:

 


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital